As previously reported, BofA analyst Adam Ron resumed coverage of Cano Health with an Underperform rating and $1.50 price target, noting that the stock is once again trading on fundamentals after a period of trading on deal speculation. While the stock could be viewed as "cheap" with shares near all-time lows, he remains cautious on the potential for further downside revisions following two guidance cuts in a row.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CANO:
- Third Point sold Cano Health stake last week, Bloomberg reports
- Cano Health downgraded at Cowen with liquidity ‘now a plausible 2023 concern’
- Cano Health downgraded to Market Perform from Outperform at Cowen
- Cano Health downgraded to Market Perform from Outperform at Raymond James
- Cano Health lowers FY22 revenue view to $2.70B-$2.75B from $2.85B-$2.90B
